Corporate Overview

Evolus is a performance beauty company building an aesthetic portfolio of consumer brands in the cash-pay aesthetic market. Our flagship product is Jeuveau®, a proprietary neurotoxin formulation used in adults to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). Supported by a unique, customer-centric business model and innovative digital platform, Evolus is increasing its presence in the fast-growing aesthetic neurotoxin market. We also recently entered into an agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development.

Read more

Evolysse™ Filler Distribution Agreement

Why Invest

$19B

Aesthetic neurotoxins and dermal fillers comprise nearly half of the $19B global medical aesthetics market1

53M

Aesthetic neurotoxin usage among the 53M millennial and younger women in the U.S. is currently very low2, reflecting a significantly underpenetrated market

10%

Our total addressable market is projected to grow 10% annually through 20283

  1. Medical Insight: The Global Aesthetic Market Study – November 2022
  2. U.S. Census Bureau, women between ages 18 and 41
  3. Represents a compound annual growth rate. Includes U.S., Canada, Europe and Australia aesthetic neurotoxin markets. Source: Medical Insight, Inc. Cosmetic Neurotoxin Market Study, Jan. 2023, Medical Insights Dermal Filler Market Study, March 2023 (www.miinews.com), BCG Aesthetic Research presented at IMCAS 2023 and company estimates.
Learn more

Latest News

View all news

Investor Presentation

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports